Causes and timing of mortality and morbidity smong late presenters dtarting antiretroviral therapy in the REALITY trial
- Post, FA
- Szubert, AJ
- Prendergast, AJ
- Johnston, V
- Lyall, H
- Fitzgerald, F
- Musiime, V
- Musoro, G
- Chepkorir, P
- Agutu, C
- Mallewa, J
- Rajapakse, C
- Wilkes, H
- Hakim, J
- Mugyenyi, P
- Walker, AS
- Gibb, DM
- Pett, SL
DOIAbstract
Background In sub-Saharan Africa, 20%–25% of people starting antiretroviral therapy (ART) have severe immunosuppression; approximately 10% die within 3 months. In the Reduction of EArly mortaLITY (REALITY) randomized trial, a broad enhanced anti-infection prophylaxis bundle reduced mortality vs cotrimoxazole. We investigate the contribution and timing of different causes of mortality/morbidity. Methods Participants started ART with a CD4 count .3); and reduced nonfatal/fatal tuberculosis and cryptococcosis (P .2). Conclusions Enhanced prophylaxis reduced mortality from cryptococcosis and unknown causes and nonfatal tuberculosis and cryptococcosis. High early incidence of fatal/nonfatal events highlights the need for starting enhanced-prop...
Add to ORKG